Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment.
Kakuda TN, Halabi A, Klein G, Sanga M, Guinard-Azadian C, Kowalik M, Nedoschinsky K, Nangosyah J, Ediage EN, Hillewaert V, Verboven P, Goris I, Snoeys J, Palmer M, Biermer M. Kakuda TN, et al. Among authors: hillewaert v. J Clin Pharmacol. 2023 Jun;63(6):732-741. doi: 10.1002/jcph.2214. Epub 2023 Mar 20. J Clin Pharmacol. 2023. PMID: 36786053
Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir).
Vandenbossche J, Yogaratnam J, Hillewaert V, Rasschaert F, Talloen W, Biewenga J, Snoeys J, Kakuda TN, Palmer M, Nangosyah J, Biermer M. Vandenbossche J, et al. Among authors: hillewaert v. Clin Pharmacol Drug Dev. 2022 Dec;11(12):1419-1429. doi: 10.1002/cpdd.1164. Epub 2022 Sep 5. Clin Pharmacol Drug Dev. 2022. PMID: 36062869 Free PMC article. Clinical Trial.
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.
Gane E, Yuen MF, Kakuda TN, Ogawa T, Takahashi Y, Goeyvaerts N, Lonjon-Domanec I, Vaughan T, Schluep T, Hamilton J, Njumbe Ediage E, Hillewaert V, Snoeys J, Lenz O, Talloen W, Biermer M. Gane E, et al. Among authors: hillewaert v. Antivir Ther. 2022 Jun;27(3):13596535221093856. doi: 10.1177/13596535221093856. Antivir Ther. 2022. PMID: 35695169 Free article. Clinical Trial.
Population pharmacokinetics of trabectedin in adolescent patients with cancer.
Poggesi I, Valenzuela B, Ouellet D, Gonzalez M, Hillewaert V, Baruchel S, Fox E, Perez-Ruixo JJ. Poggesi I, et al. Among authors: hillewaert v. Cancer Chemother Pharmacol. 2019 Oct;84(4):707-717. doi: 10.1007/s00280-019-03899-y. Epub 2019 Jul 8. Cancer Chemother Pharmacol. 2019. PMID: 31286189
Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.
Deleu S, Kakuda TN, Spittaels K, Vercauteren JJ, Hillewaert V, Lwin A, Leopold L, Hoetelmans RMW. Deleu S, et al. Among authors: hillewaert v. Br J Clin Pharmacol. 2018 Nov;84(11):2663-2672. doi: 10.1111/bcp.13733. Epub 2018 Sep 14. Br J Clin Pharmacol. 2018. PMID: 30098042 Free PMC article. Clinical Trial.
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
Bourgeois S, Horsmans Y, Nevens F, van Vlierberghe H, Moreno C, Beumont M, Vijgen L, van Eygen V, Luo D, Hillewaert V, Van Remoortere P, van de Logt J, Ouwerkerk-Mahadevan S. Bourgeois S, et al. Among authors: hillewaert v. Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01217-17. doi: 10.1128/AAC.01217-17. Print 2017 Dec. Antimicrob Agents Chemother. 2017. PMID: 28971875 Free PMC article. Clinical Trial.
18 results